- Home
- Articles
- canada quebec
- antigen target
Antigen Target Articles & Analysis
35 articles found
Single-domain antibodies, also known as nanobodies or VHH antibodies, are a unique class of antibody fragments derived from the immune systems of camelids, such as llamas and alpacas. These small yet robust molecules present significant advantages in various applications, from therapeutics to diagnostics. This article explores the process of single-domain antibody production, its benefits, and ...
Boxcab Antibody Sequencing is an important experimental method commonly used in studying cellular and protein responses. In biomedical research, antibodies are a powerful tool used in the detection and quantification of target antigens. However, a comprehensive understanding of the antibody requires knowledge of its amino acid sequence, which can be achieved through antibody sequencing.Antibody ...
Antibody-drug conjugates (ADCs) are a new class of drugs that combine the advantages of both antibodies and small molecule toxins. Compared with traditional cytotoxins, ADCs have the advantages of strong targeting, less toxic side effects, etc. They can accurately target tumor cells, reduce side effects, and improve the therapeutic effect.ADC drugs are mainly composed of monoclonal antibodies, ...
Cancer is a daunting diagnosis; however, the rapid advancements in oncology are continuously perfecting patient outcomes and quality of life. Among the groundbreaking developments, cancer vaccines are a promising frontier1. These vaccines are transforming how we approach cancer treatment, leveraging the body's immune system to fight malignancies more effectively. To grasp how cancer vaccines ...
The Unique Value and Challenges of Peptide Antigens in Antibody DiscoveryChoosing the right antigen is crucial in antibody discovery. The method of using peptides as antigens has been around for over 60 years. With technological advancements, we now have more novel avenues to choose from, such as recombinant proteins, engineered cells, and DNA encoding proteins, all of which can display a variety ...
The Latest Technological Advances in Antibody Discovery1. Single B Cell Isolation and SequencingThe isolation and sequencing of single B cells can help us gain a deeper understanding of the diversity and specificity of B cells. Through this method, we can clarify the relationship between the sequence and the cell, thus discovering antibodies with special properties. These antibodies may have high ...
From protein immunoblotting to immunofluorescence, and then to FRET, antibodies are often an important determinant of successful and repeatable experiments. But we've never had a set "plan" to find the most suitable antibody. In this issue, the editor shares a 10-step "plan" for antibody selection.Determine the Name of the Target ProteinFirst, you need to be clear about what protein you need to ...
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for ...
ByTempus
Antibody drugs, particularly monoclonal antibodies (mAb), play a critical role in the treatment of many diseases, especially in the treatment of cancer and immunological disorders. To ensure the effectiveness and safety of these antibody drugs, it is necessary to perform activity testing.Definition of Antibody ActivityThe activity of an antibody drug usually refers to its ability to bind to the ...
Nanobodies, also known as single-domain antibodies, have gained much attention in recent years due to their potential in various biomedical applications including drug delivery systems. Nanobodies are small antibody fragments derived from naturally occurring heavy-chain antibodies found in camelids, such as camels and llamas. They are composed of a single monomeric variable domain, making them ...
The development of monoclonal antibodies (mAbs) has completely transformed the field of medicine, providing targeted antidotes against a wide range of diseases, including cancer, autoimmune and infectious diseases. These therapeutic antibodies aim to specifically target antigens on the surface of cells and bind to them, leading to acidic reactions that result in the destruction of target cells. ...
With the approval of many antibody-drug conjugation (ADC) drugs around the world since 2019, conjugate drugs have developed into one of the hottest tracks in the pharmaceutical industry. Not only the research and development of traditional ADCs continues to be hot, but various new drug conjugates (NDCs) are also blooming. In this article, we make statistics on the research and development ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technology, has announced the launch of its innovative line of Chromogenic Substrates for immunohistochemistry (IHC). These cutting-edge substrates offer superior signal sensitivity, long-term storage stability, enhanced safety, and user-friendliness, empowering researchers to unlock deeper insights into ...
Luminex multiplex assays is a multi-functional, multi-indicator parallel analysis system that organically integrates color-coded beads, laser technology, applied fluidics, the latest high-speed digital signal processor and computer algorithms to create a high degree of specificity and sensitivity for multi-factor detection. It can be widely used in immunoassay, nucleic acid research, enzymatic ...
Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances (payload) through linker. ADC linker plays a key role in the therapeutic effect of ADC, and its characteristics greatly affect the therapeutic index, pharmacodynamics and ...
In the past ten years, the number of antibody drug conjugates (ADCs) entering clinical trials has steadily increased. Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for solid tumor treatment. After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. Currently, one of the most important challenges when ...
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly ...
Structurally, an ADC consists of monoclonal antibodies (Antibody) that target specific antigens on tumor surfaces, cytotoxic drugs (drugs) that kill tumor cells, and linkers (Conjugate/ linkers) that conjugate cytotoxic drugs to antibodies. The link between the antibody and linker is controlled by the coupling method, which determines the DAR value of the drug and affects the stability and PK ...
Antibodies are the precise guidance components of ADCs. In theory, molecules that bring effector molecules to the surface of tumor cells can play the role of antibody guidance The choice of antibody for ADC drugs depends on the target of the disease. Targets can be divided into tumor-specific antigens (TSA) and tumor-associated antigens (TAA) according to their expression. Antigens that are only ...
Antibody-drug conjugates (ADCs) usually consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs via chemical linkers. With high specific targeting ability and strong killing effect, it has achieved precise and efficient removal of cancer cells, and has become one of the hot spots in the development of anticancer drugs. In 2000, the FDA first approved the ADC drug Mylotarg ...